RATIONALE: Long-term outcome data following oral immunotherapy (OIT) are sparse. We previously showed high rates of sustained unresponsiveness with early-intervention peanut OIT in preschool children, and report here the first follow-up data from a longitudinal post-treatment study. METHODS: Caregivers of all 32 participants completing the parent trial were invited to complete a follow-up phone survey assessing the following domains associated with peanut consumption: Quantity, frequency, tolerability, safety, and lifestyle impact. RESULTS: Survey response rate was 75% (n524). Mean follow-up
interval was 62 months. Twenty-three subjects (96%) continue peanut consumption, including 92% who ignore precautionary labels. Twenty-two (92%) reported no allergic symptoms following ingestion; 2 (8%) reported transient mild symptoms. One subject (4%) with multiple food allergies stopped consuming peanut two years after study completion due to diagnosed eosinophilic esophagitis. Reported per-serving consumption of peanut protein (mg) was: >1000 (58%); 600-1000 (17%); 300 (17%); 100 (4%); 0 (4%). Reported frequency of consumption was: 5-7 days/week (54%); 1-4 days/week (33%); few times/month (8%); avoidance (4%). Parents of 20 participants reported feelings of increased safety and have relaxed restrictions on child activities away from home. Parents of 22 participants reported overall improvement in lifestyle quality for themselves and child. Sixteen (67%) do not see an allergist regularly. Of these, 8 (33%) had only peanut allergy and no longer carry epinephrine autoinjectors. CONCLUSIONS: Five years after early-intervention OIT, most caregivers reported improved lifestyles and safe and well-tolerated consumption of peanut. Some participants developed features suggesting sustained and prolonged clinical benefit from peanut OIT. Further follow-up is needed. METHODS: This study is a retrospective chart review of 595 PA patients (3-48 years old, mean 9 years) who received POIT over 8 years. Frequency of allergic symptoms related to a patient's peanut-specific IgE, Ara h1 and Ara h2, and skin test size were analyzed. Asthma, atopic dermatitis, and aeroallergen sensitivity were evaluated as potential risk factors for allergic symptoms. Spearman correlations were used and p<0.05 was deemed significant. RESULTS: 519 patients (87%) reached a maintenance dose of 2.5 peanuts per day. During build-up, 54 patients (9%) experienced anaphylaxis, 506 patients (85%) experienced gastrointestinal (GI) symptoms, 276 (46%) experienced cutaneous symptoms, and 118 (20%) experienced respiratory symptoms. Elevated peanut-specific IgE correlated with respiratory (p50.022) and GI (p<0.001) symptoms. Ara h1 (p50.041) and Ara h2 (p50.010) correlated with GI symptoms. Atopic dermatitis correlated with developing cutaneous symptoms during build-up phase (p<0.001). During maintenance, 98 patients (17%) experienced anaphylaxis. There was not a correlation between baseline peanut IgE or peanut components and the occurrence of adverse reactions during the maintenance phase of treatment. CONCLUSIONS: POIT is a safe therapy for patients with PA, the majority of symptoms were mild. Baseline peanut IgE, Ara h1, and Ara h2 appear to be predictive of experiencing allergic symptoms during build-up phase, but not during maintenance phase. The presence of atopic dermatitis may be predictive of cutaneous symptoms during POIT.
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Triggers and Management of FPIES in a Pediatric US population.
Andrea Blackman, and Aikaterini Anagnostou, MD MSc PhD; Baylor College of Medicine, Houston, TX. RATIONALE: Food Protein Induced Enterocolitis Syndrome (FPIES) is a non-IgE mediated reaction to food, affecting infants and young children; it can be severe and may result in shock.The aim of our study was to identify the triggers, characteristics and treatment approach of FPIES in a pediatric US population. METHODS: A retrospective electronic records' review of children presenting with FPIES over a 3-year period. RESULTS: We identified 74 cases of FPIES between 2015-2018. Median age of first episode was 5 months and median age of diagnosis was 13 months. The majority were white (90%). Female to male ratio was 1:1. 45% (34/74) of patients had atopic dermatitis, 19% (14/74) allergic rhinitis, 7% (5/74) an IgE-mediated food allergy and 7% (5/74) asthma. In 31% (23/ 74) of the patients only one trigger food was identified, while 18% (13/74) had two food triggers. In 51% (38/74), three or more trigger foods were identified and included rice (53%), milk (49%), vegetables (43%), fruits (40%), oats (35%), soy (31%), meat (13%) and fish (1%). Most patients had a negative SPT (74%, 55/74) or specific IgE (66%, 49/74) to their FPIES trigger food(s). Dietetic consultation was provided in 76% (56/74). ER visits occurred in 54% (40/74) and 24% (18/74) required hospitalization. Sepsis workup was performed in 22% (16/74) of our population and abnormal labs were found in 5% (4/74). CONCLUSIONS: In our cohort there was an 8-month delay in the diagnosis of FPIES suggesting that this condition is still under-recognized. Dietetic evaluation has increased compared with previous reports.
